Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's Zepbound.

Investors Business Daily

Novo Nordisk Foundation CEO dismisses ‘Nokia risk’ to Denmark’s economy

Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion people living with obesity.

Fortune

RFK Jr. Spooks Weight-Loss Stocks. Should Eli Lilly, Novo Nordisk Be Worried?

Robert F. Kennedy Jr.'s potential appointment to HHS has spooked Eli Lilly stock and stocks tied to popular weight-loss drugs.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

Barchart

Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk

A short strangle on Eli Lilly will generate $1,125 in option premium and takes advantage of the current high level of implied volatility.

Investors Business Daily

Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment

The efforts by Eli Lilly and Novo Nordisk could be a game-changer for sales, which some analysts say could exceed $100 billion a year.

International Business Times

Buy This Pharma Stock to Bet on the Next Blockbuster Weight-Loss Drug

A shocking study in The Lancet showed that nearly three-quarters of U.S. adults are overweight or obese. Chances are that by 2050, there will be 260 million overweight Americans. We already have GLP-1 drugs, and amylin-based drugs are next. Novo Nordisk's compound, Cagrilintide, will be combined with semaglutide in its…

Barchart

Read news from The Economist, FT, and more,
with one subscription

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

International Business Times

Could weight loss drugs fix UK’s unemployment problem?

US pharmaceuticals group Eli Lilly is to conduct trials of its weight-loss drugs in the UK.

Al Jazeera

Eli Lilly CEO's explains how failing fast leads to success

For Eli Lilly CEO Dave Ricks, speeding up the drug discovery process is essential to success.

Fortune

Amgen Rebounds. But Do Eli Lilly And Viking Therapeutics Now Have The Upper Hand?

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral density loss.

Investors Business Daily

Eli Lilly Stock: Is Wall Street Bullish or Bearish?

Eli Lilly has outperformed the broader market and its peers this year, and Wall Street analysts are bullish about the stock’s prospects.

Barchart

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Investors Business Daily

Thanks to Wall Street, Novo Nordisk Stock is Now a Buy

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Barchart

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review

The stock market retreated this week amid earnings from Microsoft, Amazon, Meta, Apple, Google and many more, along with preelection jitters.

The Street

Midday stock movers: Alphabet, Super Micro, Eli Lilly and more

Here are the stocks making the biggest market moves.

Investors Business Daily

Dow Falls As Super Micro Crashes; Meta Dives As Microsoft Gains After Results (Live Coverage)

Dow Jones stocks fell after economic data in the stock market today. Nvidia rival Advanced Micro Devices fell while a Warren Buffett stock dived after earnings.

Investors Business Daily

Dow Jones Falls After Jobs Data, GDP Report; Super Micro Plunges 30%

Stock Market Today: The Dow Jones fell Wednesday after jobs data and GDP. Google stock surged on earnings.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Eli Lilly stock crushed as weight loss sales, profits, disappoint Wall Street

Eli Lilly's weight loss treatments have powered the company into the top ten list of megacap U.S. stocks.

Investors Business Daily

Eli Lilly Plummets On Rare — But 'Big' — Sales Miss For Diabetes, Weight-Loss Drugs

Eli Lilly stock crashed Wednesday after the pharma giant cut its 2024 outlook following a "big" miss for its diabetes and weight-loss drugs.

The Street

Stock Market Today: Stocks close lower as Treasury yields climb

Another move higher in Treasury bond yields kept Wall Street in the red, with big jobs and earnings ahead as traders close out a challenging October.

Barchart

Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap

December Nasdaq 100 E-Mini futures (NQZ24) are trending up +0.28% this morning as strong quarterly results from Alphabet boosted sentiment, while investors also awaited a fresh batch of U.S. economic data and earnings reports from “Magnificent Seven” companies Microsoft and Meta.

Investors Business Daily

Dow Jones Futures Fall, Techs Rise; Google, Reddit Jump But Caterpillar, Eli Lilly, AMD Tumble

The Nasdaq hit a new high in Tuesday's mixed session. Google and Reddit jumped on earnings late. AI second fiddle AMD tumbled.

Investors Business Daily

Will New CFO Offer Annual Guidance For Google Stock?

When Alphabet reports Q3 earnings, Wall Street analysts will look for its new Chief Financial Officer, Anat Ashkenazi, to set her priorities.

Evening Standard

Ozempic, Wegovy or Mounjaro: the battle of the weight-loss injections

As weight-loss injections emerge as key players in the government’s anti-obesity strategy, Emma Loffhagen goes inside the battle between the pharmaceutical giants providing them — and delves into what exactly sets their products apart

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations